Breast cancer treatment has advanced over the past two decades, achieving a better outcome for women ([Peto *et al*, 2000](#bib34){ref-type="other"}). One of several factors contributing to improved survival is chemotherapy, which is now widely used particularly for women under 50 years and those with high-grade ER negative or lymph node-positive tumours. When chemotherapy is given prior to definitive surgical treatment, there are various potential benefits ([Valero *et al*, 2002](#bib45){ref-type="other"}): Primary tumour response provides evidence of responsiveness to the chosen chemotherapeutic agent and predicts local control ([Chollet *et al*, 2002](#bib7){ref-type="other"})A large tumour may become amenable to breast-conserving surgery ([Makris *et al*, 1997](#bib27){ref-type="other"}; [Fisher *et al*, 1998](#bib16){ref-type="other"})An ineffective therapeutic agent may be changed to one with clinical effect, or surgery may be advanced, thereby saving cost and patient suffering ([Sotiriou *et al*, 2002](#bib40){ref-type="other"}; [Pusztai *et al*, 2003](#bib35){ref-type="other"})

There is no evidence of benefit in overall or disease-free survival as a result of the use of chemotherapy in the neoadjuvant setting ([Fisher *et al*, 1998](#bib16){ref-type="other"}; [Green and Hortobagyi, 2002](#bib18){ref-type="other"}). Marginally statistically significant treatment-by-age interactions appear to be emerging for survival and disease-free survival, suggesting that younger patients may benefit from preoperative therapy, whereas the reverse may be true for older patients ([Wolmark *et al*, 2001](#bib49){ref-type="other"}). It is logical to initiate systemic treatment early in those patients with a high risk of micro-metastatic disease and to monitor the response. Conventional tools to monitor response include measurement of maximum tumour diameter with callipers; loss of signs of inflammation and reduction in lymph node size. Serial core biopsy has been used to show changes in tissue morphology by standard histological criteria and more recently with molecular markers ([Sotiriou *et al*, 2002](#bib40){ref-type="other"}; [Pusztai *et al*, 2003](#bib35){ref-type="other"}). Response of the primary tumour or regional nodes may be monitored radiologically with mammography or ultrasound ([Helvie *et al*, 1996](#bib20){ref-type="other"}; [Vinnicombe *et al*, 1996](#bib46){ref-type="other"}; [Huber *et al*, 2000](#bib23){ref-type="other"}); and newer imaging modalities ([Mankoff *et al*, 1999](#bib28){ref-type="other"}; [Tiling *et al*, 2001](#bib42){ref-type="other"}), such as contrast-enhanced (CE) MRI are being increasingly used. The literature contains many single institution reports of the use of breast MRI for monitoring tumour response or predicting tumour extent prior to surgery. [Table 1](#tbl1){ref-type="table"} Table 1Existing literature on the use of breast MRI to monitor response to chemotherapy**AuthorOriginYearNumberMeasurementPathology response**[Knopp *et al* (1994)](#bib25){ref-type="other"}Heidelberg, Germany1994Three case studies Promising prediction[Gilles *et al* (1994)](#bib17){ref-type="other"}Villejuif, France199418 (15 out of 18) 83% Highly predictive of residual tumour[Abraham *et al* (1996)](#bib1){ref-type="other"}Dallas & Little Rock, USA199639 MRI correctly predicted residual disease in 30 out of 31 (97%)[Rieber *et al* (1997)](#bib37){ref-type="other"}Ulm, Germany199713 Underestimates residual tumour[Trecate *et al* (1998)](#bib43){ref-type="other"}Milano, Italy199827 Valid tool for monitoring response[Tsuboi *et al* (1999)](#bib44){ref-type="other"}Kochi, Japan199931 Valuable for predicting response and margins[Weatherall *et al* (2001)](#bib47){ref-type="other"}Dallas, TX, USA200122Cc0.93MR, 0.63 mamAccurate assessment of residual tumour[Nakamura *et al* (2001)](#bib30){ref-type="other"}Tokyo, Japan200115 Predict possibility of WLE. Mapping of dendritic tumours[Drew *et al* (2001)](#bib10){ref-type="other"}Hull, UK200117Sensitivity 100%Accurate method of predicting residual tumour[Esserman *et al* (2001)](#bib14){ref-type="other"}UCSF200133 Patterns of tumours identified[Partridge *et al* (2002)](#bib33){ref-type="other"}UCSF200252R0.89, C0.60MRI detected all residual disease[Balu-Maestro *et al* (2002)](#bib3){ref-type="other"}Nice, France200260 in 51 women Valuable tool for size & multifocality prior to surgery[Rieber *et al* (2002)](#bib36){ref-type="other"}Ulm, Germany200258Accuracy NR 83.3%, PR 82.4%Good for assessing response to chemo, unreliable in CR cases where 66.7% had residual tumour[Cheung *et al* (2003)](#bib6){ref-type="other"}Kwei San, Taiwan200333 Useful to assess early response and predict tumour size change[Delille *et al* (2003)](#bib9){ref-type="other"}Harvard, USA200314EFP~count~ accurate measure (*P*\<.02)Extraction flow product as marker of tumour response summarises the literature to date on the use of breast MRI to monitor neoadjuvant chemotherapy. It can be seen from the right-hand column of this table that the findings have varied very substantially. Breast MRI appears to hold promise for this purpose, and provides measurements that are more accurate than clinical or ultrasound assessment ([Davis *et al*, 1996](#bib8){ref-type="other"}; [Esserman *et al*, 1999](#bib13){ref-type="other"}). It is important to know whether predictions of residual tumour are accurate. Breast MRI has good sensitivity for invasive tumour but relatively poor specificity in untreated disease ([Mussurakis *et al*, 1996](#bib29){ref-type="other"}). The limitations are more apparent for invasive lobular carcinoma and *in situ* ([Kinkel and Hylton, 2001](#bib24){ref-type="other"}). Contrast-uptake characteristics have been shown to be altered by chemotherapy, which may potentially diminish sensitivity and impair specificity ([Rieber *et al*, 1997](#bib37){ref-type="other"}). Contrast uptake characteristics have been used to give an early indication of tumour response using innovative functional MR and computer methods ([Padhani, 2002](#bib32){ref-type="other"}; [Delille *et al*, 2003](#bib9){ref-type="other"}). It is therefore an open question whether CE MRI would be helpful in monitoring response, or whether limitations emerging from studies undertaken concurrent with this one would make it unreliable.

In this study, we have investigated the impact of breast MRI on decision-making. Almost all of our patients underwent mastectomy after neoadjuvant chemotherapy. It is therefore possible to correlate the extent of tumour detectable on breast MRI following chemotherapy with histopathology of the mastectomy specimen. The aims of our study were: To determine whether CE MRI is an accurate indicator of tumour response to neoadjuvant chemotherapy in comparison to the histopathology gold standard.To assess whether CE MRI increases the diagnostic confidence above that achieved by conventional assessment methods (CAM) (i.e. clinical examination, ultrasound and mammography)To determine whether CE MRI can accurately identify a subset of patients who might be suitable for breast-conserving surgery following neoadjuvant chemotherapy.

PATIENTS AND METHODS
====================

Patients and chemotherapy
-------------------------

The study had approval from the Local Research Ethics Committee for Cambridgeshire, and all women had given informed consent to participate. It is a retrospective review of 67 women with CE-MRI before and after neoadjuvant chemotherapy for breast cancer. The first 30 women were recruited between 1997 and 2001 to a prospective pilot study of CE MRI. The remaining 37 women were consecutively enroled once CE MRI monitoring became the standard of care at our centre in 2001. The decision to give neoadjuvant therapy was made by a multidisciplinary team, and in general included women less than 60 years with large, inflammatory or high-grade tumours. Chemotherapeutic regimens used in this series varied according to whether patients were treated in ongoing clinical trials ([Appendix A](#tbla1){ref-type="table"}). All cases had undergone mammography, ultrasound and core biopsy prior to the decision to treat with neoadjuvant chemotherapy, and the results of these tests were used by the team to determine which trials they should enter.

Contrast enhanced MRI (CE MRI)
------------------------------

The patients had two MRI studies, at the start of treatment and prior to surgery. The initial MRI study was usually undertaken prior to the first course of chemotherapy except in occasional cases where limitations of access to MRI resulted in imaging after the first treatment had been given. The 2nd MRI study was performed after all chemotherapy and prior to surgery. The studies were undertaken on a 1.5 T magnet from GE Signa Echospeed, which was upgraded in 2002 with Excite software. The MRI technique is similar to that described for the MARIBS study ([Brown *et al*, 2000](#bib5){ref-type="other"}), with the exceptions that the dose of gadolinium was 0.16 mmol kg^−1^ body weight, and no proton density study was undertaken in our study (Scanning protocol -- [Appendix B](#tbla3){ref-type="table"}). MRI interpretation used a synthesis of dynamic and morphological features, including the pattern of contrast uptake and washout characteristics, and the studies were examined at the console to allow dynamic contrast enhancement curves at any point in the 3D volume of the dynamic acquisition. The studies were reported by radiologists and presented to the multidisciplinary team for decisions on patient management.

Conventional methods of assessment
----------------------------------

All patients had a clinical assessment prior to each of six cycles of chemotherapy. This included calliper measurement of tumour size, degree of inflammation and size of palpable axillary nodes. All patients underwent mammography, ultrasound and core biopsy for diagnosis. Ultrasound was carried out after three and six cycles of chemotherapy. Conventional breast imaging comprised mammography, ultrasound and core biopsy according to the guidelines of the United Kingdom National Health Service Breast Screening Programme (NHSBSP) ([Wilson *et al*, 2001](#bib48){ref-type="other"}).

Surgery
-------

Surgery normally took place less than 4 weeks after the last course of chemotherapy. All patients underwent either mastectomy or wide local excision (WLE) with axillary lymph node dissection.

Histopathological response
--------------------------

Response to treatment was scored by standard UICC ([Therasse *et al*, 2000](#bib41){ref-type="other"}) categories of Complete Response (CR), Partial Response (PR), Non-Response (NR), Disease Progression (DP). The reports were produced at the time of clinical care without particular knowledge of the MRI findings. It should be noted that after chemotherapy the criteria for grading cannot be applied, and so when grades are given here they are based on core biopsy ([Harris *et al*, 2003](#bib19){ref-type="other"}).

There are no recognised standard criteria for grading of histological response following primary chemotherapy. In this study, mastectomy specimens were handled according to the NHSBSP guidelines ([NHSBSP publication No. 3, 1995](#bib31){ref-type="other"}). In addition, in those cases where no macroscopic tumour could be identified, extensive sampling of the original tumour site (as identified by imaging methods and clinical examination prior to treatment) was performed.

On histological examination, where distinct *in situ* and invasive tumour was identified this was morphologically compared with tumour seen on the original core biopsy. The ratio of tumour cell mass to surrounding tissue was evaluated. If degenerative changes within tumour cells were present this was noted. The nature of the tissue surrounding tumour cells was noted, viz was it a cellular stroma similar to that seen in the original biopsy or was it inflamed, hypocellular scar tissue.

Thus: *No histological response*. Tumour resembling that in the original core biopsy was present and it extended within the breast tissue for the same or a greater distance than originally estimated by imaging and clinical examination. The nature of the tissue surrounding the tumour was cellular and did not resemble bland scar tissue.*Complete histological response*. Absence of invasive carcinoma cells/or \<1single, degenerate carcinoma cell/10 high-power fields. Absence of *in situ* carcinoma.*Partial histological response*. Tumour resembling that in the original core biopsy but which was considerably reduced in size (it is necessary to approximate size parameters used in clinical response staging). Presence of residual microscopic foci of invasive carcinoma but with reduced tumour cell/stroma ratio or residual pure *in situ* carcinoma.

Assessment of sensitivity, specificity of conventional assessment methods and CE MRI
------------------------------------------------------------------------------------

Original records were used to score clinical response using CAM, CE MRI response and histopathological response, and from these sensitivity and specificity were calculated. Pathological response was regarded as the gold standard against which all evaluations of response were measured.

Assessment of diagnostic impact and confidence of knowledge
-----------------------------------------------------------

For the purposes of this study, all cases were reviewed by the multidisciplinary team and a research form completed to record the diagnostic impact. The review team consisted at minimum of a radiologist, a surgeon, an oncologist and a histopathologist, all expert in management of breast disease. The multidisciplinary review procedure is shown in [Figure 1](#fig1){ref-type="fig"}Figure 1Algorithm for recording findings in the multidisciplinary meeting.. The clinical notes were examined for the clinical findings recorded at the time of clinical care. The mammograms and ultrasound images with their original reports were presented as in a standard multidisciplinary team meeting. The MRI studies were presented to the clinical team using the images and reports taken at the time of clinical care of the patients. The multidisciplinary team were unaware of the histopathology findings when they interpreted the results of the MRI and other presurgical examinations. The pathology was presented from the histological report at the time of clinical care, and did not take particular account of MRI knowledge. The added value of MRI imaging was given a score 1...6 ([Figure 2](#fig2){ref-type="fig"}Figure 2Value of including MRI imaging.) by the team, taking into account the additional contribution made by the MRI study beyond that available with conventional breast imaging ([Shuman *et al*, 1985a](#bib38){ref-type="other"},[1985b](#bib39){ref-type="other"}). A visual analogue scale was used to record confidence of knowledge with conventional breast imaging alone and with the addition of MRI ([Blanchard *et al*, 1997](#bib4){ref-type="other"}). Confidence of knowledge included knowledge of the size, the contour, the extent and the suitability for any form of surgery. The two measures, added value and confidence of knowledge are complementary, since confidence of knowledge is an important aspect of value to a clinician. These are subjective clinical judgements.

Statistical analyses
--------------------

Proportions in independent samples were compared using Fisher\'s exact test or linear by linear χ^2^ test as appropriate. Parametric and nonparametric paired comparisons of mean and median values were performed using the paired *t*-test and McNemar test, respectively. The relationship between initial tumour size and subsequent tumour response was assessed using one-way analysis of variance. Statistical significance was accepted at the conventional *P*\<0.05 threshold.

RESULTS
=======

The study evaluated 69 cancers in 67 women including two bilateral cases. In all, 67 cancers were treated with mastectomy and two with WLE. The mean age of the patients at the time of the 1st MRI was 46.2 (range 28 to 62 years). On initial radiological examination, the median size of the 69 tumours was 49.0 mm (range 9--100 mm). The core biopsy demonstrated that six (9%) tumours were grade 1, 25 (36%) grade 2 and 38 (55%) grade 3. These therefore represent relatively large, poor prognosis cancers in younger women. In total, 36 (52%) tumours were oestrogen receptor (ER) positive, and 33 (48%) ER negative, 21 out of 26 (81%) patients where the progesterone receptor (PR) status was recorded were PR negative. At definitive surgery, patients had a median of 13 nodes retrieved (range 0--42); 17 patients (25%) had more than four nodes involved, 23 (33%) had between one and four nodes involved, and 29 (42%) were node negative. In all, 12 (17%) patients presented with inflammatory cancers, 31 (45%) were known to be multifocal or diffuse lesions by their imaging or clinical findings, and a further 16 (23%) lesions were close to the nipple--areolar complex. After the initial clinical and radiological evaluation, a total of 52 (75%) tumours were considered not suitable for breast conservation within the protocols of our unit, where skin involvement by inflammation, very large size, multifocality and proximity to the nipple--areolar complex are all viewed as reasons for not using breast-conserving surgery. The median period between the 1st and 2nd MR imaging was 119 days (range 48--165 days). The median period between the 2nd MR and surgery was 24 days (range 2--77 days). The neoadjuvant chemotherapy included cases in trials, notably Anglo-Celtic 2, and cases off trial with a variety of regimens ([Appendix A](#tbla1){ref-type="table"}).

Estimation of response
----------------------

Based on the gold standard histopathology findings, 12 lesions (17%) had complete response, 47 (68%) had partial response, 10 (15%) had no response following neoadjuvant chemotherapy ([Table 2](#tbl2){ref-type="table"} Table 2Comparison of clinical assessment with ultrasound and mammography and pathology rating of tumour response  **Conventional assessment methods (CAM) Clinical examination+mammography and ultrasound**  **Complete responsePartial responseNo responseDisease progression**Pathology findingsComplete response9300 Partial response133310 No response1450 Disease progression0000). There was no significant association between the grade of the tumour and the extent of disease response following chemotherapy. In total, 24% (nine out of 38) of grade 3 tumours had complete response to chemotherapy compared to 12% (three out of 25) of grade 2 tumours and 0% (zero out of six) of grade 1 tumours (*P*=0.10). Four out of 36 (11%) ER-positive tumours exhibited complete response at pathology compared to six out of 21 (29%) of tumours that were ER- and PR negative (*P*=0.15). Lesions that did not respond or progressed after neoadjuvant chemotherapy were slightly, but nonsignificantly, larger than lesions that exhibited partial or complete response (mean size 56 *vs* 49 *vs* 48 mm; *P*=0.56). Tumour response was clearly related to the extent of node involvement. In all, 97% (28 out of 29) of lesions with no node involvement had complete or partial response compared to 87% (20 out of 23) of lesions with between one and four positive nodes and 65% (11/17) lesions with more than four involved nodes (*P*\<0.01).

Conventional assessment methods and MRI in the estimation of tumour response
----------------------------------------------------------------------------

The clinical assessment of tumour response agreed with the pathology assessment in 47 out of 69 tumours (68%) ([Table 2](#tbl2){ref-type="table"}). CAM underestimated the degree of response in four cases, and overestimated the degree of response in 18 cases. In one case, a tumour which was categorised as completely responsive based on the clinical data had no response evident at pathological examination. CAM correctly identified 58 out of 59 lesions with complete or partial response based on pathology findings (sensitivity 98%; 95% confidence interval (CI) 91--100%). However, five out of 10 tumours with no response were incorrectly categorised as complete or partial response on the clinical assessment (specificity 50%; CI 19--81%).

There was agreement between MRI findings and the pathology findings in 56 out of 69 lesions (81%) ([Table 3](#tbl3){ref-type="table"} Table 3Comparison of MRI and pathology rating of tumour response  **CE MRI findings**  **Complete responsePartial responseNo responseDisease progression**Pathology findingsComplete response12000 Partial response103700 No response1171 Disease progression0000). The imaging findings underestimated the effect of chemotherapy in one case where disease appeared to have progressed on CE MRI, but where pathology results indicated no response. In a further 12 cases, MRI overestimated the response to therapy. The sensitivity (100%; CI 94--100%) and specificity (80%; CI 44--97%) of MRI for identifying complete or partially responsive tumours were higher than for the clinical assessment alone. The absolute agreement between MRI and pathology findings was marginally higher than the agreement between clinical assessment and pathology findings (81 *vs* 68%; *P*=0.09).

Diagnostic confidence and therapeutic impact after MRI
------------------------------------------------------

In the majority of cases, the 2nd MRI study was judged to increase diagnostic knowledge (\>70% see [Table 4](#tbl4){ref-type="table"} Table 4Potential diagnostic and therapeutic impact of 2nd MRI**Impact of MRI*N* (%)***Diagnostic knowledge with 2nd MRI* Better49 (71%) Same8 (12%) Worse12 (17%)  *Diagnostic value of 2nd MRI* Confusing or incorrect -- extra studies required0 (0%) Confusing or incorrect -- no extra studies14 (20%) No change in treatment plan6 (9%) No change in treatment plan -- increased diagnostic confidence36 (52%) Could have caused change in treatment plan10 (15%) Caused change in the treatment plan3 (4%)  *Diagnostic confidence of 2nd MRI* Without 2nd MRI (mean (s.d.))5.8 (1.8) With 2nd MRI (mean (s.d.))7.9 (2.0)^\*^  *Therapeutic impact of 2nd MRI*WLE possible based on surgery22/69 MRI agrees with conventional assessment, WLE possible10 (45%) MRI agrees with conventional assessment, WLE NOT possible5 (23%) MRI disagrees with conventional assessment, suggests WLE possible5 (23%) MRI disagrees with conventional assessment, suggests WLE NOT possible2 (9%)  WLE NOT possible based on surgery47/69 MRI agrees with conventional assessment, WLE possible4 (9%) MRI agrees with conventional assessment, WLE NOT possible35 (75%) MRI disagrees with conventional assessment, suggests WLE possible4 (9%) MRI disagrees with conventional assessment, suggests WLE NOT possible4 (9%)[^1]). However, in a substantial proportion of cases (17% see [Table 4](#tbl4){ref-type="table"}) the 2nd MRI was judged to have reduced diagnostic knowledge. These 12 cases have been examined in greater detail -- see [Table 5A](#tbl5){ref-type="table"} Table 5Cases in which the 2nd MRI study (A) reduced diagnostic knowledge *n*= 12 and (B) either did or had the potential to alter the treatment plan *n*=13**CaseAge, yearsClinical size, mm at start of treatmentGradeERQuadrants involvedSpaced out cells presentDCIS presentcRmRpRComments**(A)1^a^,^b^46501+MultifocNoNo112Underestimates residual tumour2^a^,^b^51Unmeasurable2+UnifocalNoNo212Underestimates residual tumour6^a^,^b^4760+3+SubareolNoYes212Underestimates residual tumour ILC8^b^41Unmeasurable3−DiffuseNoYes122Underestimates residual tumour13^b^54402+UnifocalNoYes112Underestimates residual tumour25^b^3960+3−DiffuseNoYes113Underestimates residual tumour29^a^,^b^3460+3−SubareolNoYes111No contrast -- failed injection CR report30^a^4960+2+UnifocalYesYes212Underestimates residual tumour DCIS31^a^,^b^5160+2+MultifocNoYes222Underestimates residual tumour32^b^40453−MultifocNoNo222Underestimates residual tumour34^a^43303−UnifocalNoYes211Residual DCIS41^a^,^b^3460+2+MultifocNoYes122Underestimates residual tumour ILC61^a^,^b^4760+1+MultifocNoYes212Underestimates residual tumour63^a^,^b^60Unmeasurable3+DiffuseNoYes223Underestimates residual tumour66^a^,^b^47453+SubareolNoYes222Underestimates residual tumour78^a^,^b^2860+2−UnifocalYesNo212Underestimates residual tumour            (B)752Unmeasurable2−UnifocalYesYes112Could have endorsed WLE1449403−UnifocalNoYes222Better estimate of residual tumour214760+2+SubareolNoYes322Could have endorsed WLE3443302−UnifocalNoYes211Could have endorsed WLE DCIS only3757541−MultifocNoNo111Could have endorsed WLE4456403−UnifocalNoNo122Confirmed residual tumour5243502+SubareolNoYes233Showed nonresponder. Skin thickening5543303+UnifocalNoYes111Could have endorsed WLE5952403+UnifocalYesYes111Could have endorsed WLE62bilat4960+2+DiffuseNoYes222Contralateral tumour shown6733323+MultifocNoNo222Did not confirm multifocality suspected on ultrasound. Could have endorsed WLE7137552−SubareolNoNo111Could have endorsed WLE[^2][^3][^4][^5][^6].

In the majority of patients the 2nd MRI study did not change the treatment plan but did increase diagnostic confidence (52%, [Table 4](#tbl4){ref-type="table"}). This confidence was clearly valued by clinicians. Again, in a substantial minority of cases (20%, [Table 4](#tbl4){ref-type="table"}) the MRI findings were thought to be confusing or incorrect. In the majority of these cases, the problem stemmed from the MRI study underestimating the amount of residual tumour by suggesting a complete response when, in fact, there were residual invasive tumour cells or DCIS. These cases have been examined more closely and the findings set out in [Table 5A](#tbl5){ref-type="table"}. In a further 19% of cases ([Table 4](#tbl4){ref-type="table"}) the 2nd MRI either did, or had the potential to alter the treatment plan. These cases have been summarised in [Table 5b](#tbl5){ref-type="table"}. The reasons included a contralateral nonpalpable tumour, complete response that could have allowed breast conservation, demonstration of nonresponse, demonstration of a single focus where multifocality was suspected. The mean diagnostic confidence for all patients significantly increased from 5.8 pre-2nd MRI to 7.9 post-2nd MRI (*P*\<0.01; [Table 4](#tbl4){ref-type="table"}).

Surgical findings indicated that WLE would not have been possible following neoadjuvant chemotherapy in 47 out of 69 lesions ([Table 4](#tbl4){ref-type="table"}). In 35 out of these 47 cases, both conventional assessment and MRI correctly predicted the need for mastectomy. The remaining 12 cases were evenly split between cases where conventional assessment incorrectly predicted WLE was possible (4), cases where MRI incorrectly predicted WLE was possible (4), and cases were both presurgery evaluations incorrectly suggested that breast-conserving surgery was possible (4).

In all, 10 out of the 22 lesions (46%) where surgical findings demonstrated that WLE would have been feasible were correctly identified by both conventional assessment and MRI ([Table 4](#tbl4){ref-type="table"}). In five cases, MRI correctly contradicted the conventional assessment by suggesting that WLE was possible. However, in the remaining seven cases MRI suggested that WLE was possible when surgical findings indicated that it was not. The overall agreement with surgical findings regarding the feasibility of WLE was 74% (51 out of 69) for conventional assessment and 78% (54out of 69) for MRI (*P*=0.44). Cases where the 2nd MRI study disagreed with surgical findings regarding the possibility of WLE are summarised in more detail in [Table 6](#tbl6){ref-type="table"} Table 6Cases where the 2nd MRI study disagreed with surgical findings regarding the possibility of WLE**Case no.Age in yearsRadiological size, mmCore biopsy gradeERInitial assessment allows WLEMRI2 indicates WLE possibleFinal pathology indicates WLE possibleDCIS present in final pathologySpaced out cells present in final pathologyComments** 146601+NoNoYesNoNo15 mm unifocal 438702+NoNoYesYesNo22 mm unifocal1449343−YesNoYesYesNo31 mm unifocal2244193−NoNoYesNoNoNo residual tumour2745353+NoNoYesNoNoNo residual tumour3151582+NoNoYesYesNo25 mm unifocal6249392+NoNoYesYesNo20 mm unifocal 251552+YesYesNoNoNoMultifocal 647533+NoYesNoYesNoWidespread residual1041512+NoYesNoYesNo41 mm residue1160383−NoYesNoNoNoMass+scattered foci1354342+YesYesNoYesNoMultifocal29341003−NoYesNoYesNoCR but inflammatory at outset3843602+NoYesNoYesNoWidespread foci6147501+NoYesNoYesNoMultifocal.

DISCUSSION
==========

To achieve the objectives of neoadjuvant timing in the use of chemotherapy, it is necessary to understand the available preoperative methods of assessing response. Assessment of response to permit conservation surgery and to judge the effectiveness of the chemotherapy and the biological responsiveness of tumours are both important. Clinical methods have been unreliable ([El-Didi *et al*, 2000](#bib11){ref-type="other"}), and there are clear limitations in the power of mammography ([Huber *et al*, 2000](#bib23){ref-type="other"}) or ultrasound (for this purpose, ultrasound is widely used, but very poorly researched) to provide accurate information. CE breast MRI has attractions for this purpose, since it has high sensitivity for invasive tumour and is dependent on increase in vessel density and abnormal diffusion properties of tumour blood vessels for its mode of visualisation. It is essentially a tomographic technique, able to give attractive 3D images that can aid surgeons in planning their operative procedures ([Figure 3](#fig3){ref-type="fig"}Figure 3A subtracted image of a large tumour of the left breast before and after neoadjuvant chemotherapy. (**A**) and (**B**) reconstructed in the axial plane, (**C**) and (**D**) in the coronal plane. The patient was aged 52 years, had a clinically immeasurable tumour involving the nipple and so not suitable for WLE. It was grade 3, ER positive. She was treated with adriamycin and cyclophosphamide 6 cycles, off-study. She had a complete clinical response, but final histology showed residual grade 3 tumour with associated high-grade DCIS. The MRI studies show the considerable response, but correctly predicted residual tumour over a substantial volume, confirmed as over 60 mm on final histology.).

There have been a number of studies testing CE breast MRI for this purpose, which have been summarised in [Table 1](#tbl1){ref-type="table"}. The conclusions of these studies have varied considerably and several of them have an up-beat approach that may give surgeons and oncologists false expectations of the capacity of the technique to be reliable in all the aspects needed for planning treatment. Our study is from a single multidisciplinary team in two hospitals, with clinical work of several experts in each discipline. We have used the contemporary reports and notes of the cases to assess the impact, real or potential, on clinical care provided by a CE MRI study at the start and end of neoadjuvant chemotherapy. We have used the histopathological response as the gold standard and since most of our patients had mastectomy, we have the potential to judge whether WLE could have been achieved. By using the full multidisciplinary team in evaluating each case, we hope to have avoided the bias that might ensue from radiologists alone assessing their value. Diagnostic and therapeutic impact methodology has been used for assessment of other new diagnostic procedures ([Shuman *et al*, 1985b](#bib39){ref-type="other"}) including MRI ([Hollingworth *et al*, 2000](#bib21){ref-type="other"}) for other purposes. We have moulded this methodology to apply to the present clinical scenario, for example by including an extra category -- 'MRI results could have caused a measurable change in the original plan'.

A few patients had their MRI study after the first cycle of chemotherapy was given, but these cases have not been excluded because the end points in this analysis relate to the presurgical MRI findings. The range of length between the 2nd MRI and surgery is determined by difficulties with scheduling of both MRI studies and reconstructive surgery in our hospital. The range of times between 1st and 2nd MRI studies is determined by the different regimens and patient episodes such as depression of white count which may have delayed cycles of chemotherapy. Whether these variations are important to the end points of this analysis is a matter of speculation, but they relate to pressures that would apply to real-life use of MRI out of the study setting. Our patients received a variety of chemotherapeutic regimens but this should make our CE MRI evaluation generalisable to actual clinical practice where chemotherapy choices vary. The analysis of the MRI study is not affected by the different chemotherapy regimens.

We have made the main comparison of sensitivity and specificity between clinical examination coupled with conventional breast imaging (mammography and breast ultrasound) and CE MRI. CE MRI had both better sensitivity and specificity than clinical measures in conjunction with conventional breast imaging for detecting complete or partial response. The sensitivity of conventional methods is high, but there are serious limitations in specificity. In all, 50% (five out of 10) of patients with no response on pathology were incorrectly classified as partial or complete responders on clinical assessment, mammography and ultrasound. The specificity of CE MRI was higher (eight out of 10), but, due to the small number of patients who did not respond to chemotherapy, this result did not reach statistical significance. Furthermore, CE MRI still gives erroneous results in a number of cases. This is demonstrated in [Table 5a](#tbl5){ref-type="table"} where it is seen that the commonest limitation of the value of CE MRI is to underestimate residual tumour when compared with final pathology. Several authors ([Gilles *et al*, 1994](#bib17){ref-type="other"}; [Drew *et al*, 2001](#bib10){ref-type="other"}; [Weatherall *et al*, 2001](#bib47){ref-type="other"}; [Partridge *et al*, 2002](#bib33){ref-type="other"}) have found very good prediction of residual tumour by breast MRI, whereas Rieber in two studies had findings similar to ours ([Rieber *et al*, 1997](#bib37){ref-type="other"}, [2002](#bib36){ref-type="other"}). We wish to seek the explanation for this in greater detail, and will do so by a separate publication studying the dynamic analysis compared with detailed pathology. Many of the cases with small amounts of residual tumour have islands of invasive cells or of DCIS spread across the area previously occupied by the treated tumour. The contrast uptake of the CE MRI did not distinguish this minimal residual disease (MRD) from any background uptake within the glandular tissue of the breast. The chemotherapeutic agents attenuate the contrast uptake characteristics, rendering the curves on some occasions benign in appearance. Clinical assessment of response is based on the size of the palpable mass and the clinical evidence of reduction in lymphoedema or in lymph node size. CE MRI was shown here to be better than these clinical findings even when they are backed up by ultrasound.

The cases in which CE MRI gave added value are shown in [Table 5b](#tbl5){ref-type="table"}. These are demonstration of unsuspected contralateral tumour, endorsement of a decision for WLE, better demonstration of nonresponse by showing skin thickening, better estimate of residual tumour and proof of unifocal disease. In [Table 6](#tbl6){ref-type="table"}, we have scrutinised the performance of CE MRI in predicting the possibility of WLE after neoadjuvant chemotherapy. It was a surprise to us that so few cases were suitable for breast-conserving surgery from the start, and we do not have the power here to show whether MRI was helpful in a significant way when only the cases which from the outset could have been suitable are considered.

It has been shown that pathological response is predictive of survival ([Kuerer *et al*, 1999](#bib26){ref-type="other"}; [Amat *et al*, 2002](#bib2){ref-type="other"}; [Chollet *et al*, 2002](#bib7){ref-type="other"}) and that outcome is predicted also by tumour grade and nodal involvement. It would be useful to know whether complete response on MRI is predictive of outcome, even when it fails to identify isolated foci of malignant cells or residual DCIS. If response on MRI were to be predictive of survival or disease-free survival, then this would be a test that gave predictive information prior to surgery and full pathology. Many more cases than the present study would be required to answer this question.

Within this series, the grade 3 and ER negative tumours tended to have a slightly better probability of complete response than the lower grade, ER-positive tumours, however neither of these differences reached statistical significance. A factor to consider here is the under staging that occurs with core biopsy, where 70% of cases have been shown to be upstaged between core biopsy and definitive surgical histology ([Harris *et al*, 2003](#bib19){ref-type="other"}). After chemotherapy, we do not have satisfactory grading, and so the grades discussed here are all from core biopsy. The response rate that has been recorded cannot be appraised since it is dependent on the case selection for use of neoadjuvant chemotherapy and the different regimens in use, neither of which have been made standard in this study. We are looking at the effectiveness of CE MRI as a tool for monitoring, not at response rates in themselves. Our study shows that our MRI findings had very serious limitations in predicting the possibility of undertaking wide local excision after neoadjuvant chemotherapy, and that the shortfall was in both directions and not predictable from any particular characteristics of the cases. This study also shows how inaccurate clinical assessment of tumour response is, even when enhanced by ultrasound or mammography.

Even though our study has shown definite limitations to the reliability of MRI, the clinical team found that it provided valuable additional information. The problems with CE MRI are sufficient to continue to seek improved methods of assessing tumour response. Functional MRI, PET scanning and molecular imaging are emerging techniques that may offer more accurate information.

CONCLUSION
==========

Our study suggests that CE MRI may have better sensitivity and specificity for predicting complete or partial response than clinical examination with conventional imaging. Moreover, the absolute agreement between MRI and pathology findings was marginally higher than the agreement between clinical assessment and pathology findings. CE breast MRI is robust in predicting nonresponse and disease progression. Our clinicians valued the visual images that are obtained which show tumour response. They feel that they give additional information -- probably by giving a better measure of size and providing images that help them to understand the permeative properties of the tumour. In our series, MRI persistently underestimates residual malignancy where the tumour is not a single mass, and this may be a problem in some cases when it is used to predict the possibility of WLE.

The study was made possible by a grant from Addenbrooke\'s Charities. The patients were under the clinical care of Cambridge Breast Unit and Hinchingbrooke Hospital and MRI studies were undertaken by Chris Pittock, Anna Crawley, Ilse Joubert, Joanna Cook and Hayley Eales. Thanks are due to the following clinicians who have contributed cases, but are not cited as authors: Alan Freeman, Ruchi Sinnatamby, David Gilligan, Carlos Caldas, Oduru Ravisekar, Karen MacAdam, Charles Wilson, and to the following who have contributed their expertise: Adrian Dixon, David Lomas, Martin Graves, Richard Black, Clare Sims. Iqbal Warsi completed the data gathering and dataset cleaning and Jackie Green gave administrative support throughout.

See [Tables A1](#tbla1){ref-type="table"} Table A1Chemotherapy regimens in use ***n***Doxorubicin/cyclophosphamide six cycles41Doxorubicin/docetaxel six cycles21Epirubicin four cycles then CMF four cycles2Epirubicin four cycles2Docetaxel/Herceptin1Total67[^7] and [A2](#tbla2){ref-type="table"}Table A2Cases included in the study**CaseAgeSizeInflGrERPgRHistTrialcRmRpR**014660n1+ IDCAC2cCRmPRpPR025155n2+ IDCAC2cPRmPRpPR035165n3+ IDC cCRmPRpPR504055n3−−IDC cCRmPRpPR464495n3−−IDC cPRmPRpPR043870n2+ IDCAC2cPRmPRpPR055545n1+ IDC cPRmPRpPR064753n3+ ILCAC2cPRmCRpPR075270n2−0IDCAC2cCRmCRpPR513148n2+−−IDC cPRmCRpCR084170y3−−IDCAC2cCRmPRpPR104151n2+ ILC cPRmPRpPR116038n3−+IDC cPRmPRpPR125688y1+ IDC cNRmNRpNR426165n3−−IDC cNRmNRpNR135434n2+ IDCAC2cCRmCRpPR413469y2+ ILCAC2cCRmPRpPR144934n3−−IDC cPRmPRpPR406134n3+ IDCAC2cPRmCRpPR155432n3+ IDCAC2cCRmPRpPR163953y3−0IDC cNRmDPpNR595255n3+ IDCAC2cCRmCRpCR174970y2−0IDC cPRmPRpPR184749n3−−IDCAC2cPRmPRpPR544969y3−−IDCAC2cCRmCRpCR554335n3+ IDCAC2cCRmCRpCR193550n3−+IDCAC2cPRmPRpPR204590y2+ IDC cPRmPRpPR214745n2+ IDCAC2cNRmPRpPR4730 n3−+IDC cPRmNRpNR224519y3−−IDCAC2cPRmCRpCR234940n3−−IDCAC2cPRmPRpPR435046n3−−IDCAC2cPRmPRpPR394439n3+ IDCAC2cCRmCRpCR253945n3−−IDCAC2cCRmCRpNR263326n3−−IDCAC2cPRmPRpCR274535n3+ IDC cCRmCRpCR574736n3−−IDCAC2cPRmNRpNR2934100y3−−IDC/ILC cCRmCRpCR304954n2+ IDCAC2cPRmCRpPR315158n2+ IDCAC2cPRmPRpPR324044n3−−IDCAC2cPRmPRpPR334190y3+ IDC cCRmPRpPR344330n3−0IDCAC2cPRmCRpCR585966n3−−IDC cPRmPRpPR354966n2+ IDC cNRmNRpNR364549n2+ ILCAC2cPRmPRpPR614550n3+ IDCAC2cPRmCRpPR375764n2−−ILCAC2cCRmCRpCR384360y2+ IDCAC2cCRmPRpPR[^8].

See [Table B1](#tbla3){ref-type="table"}Table B1MR pulse sequence protocol for a breast MR examination in use for this study**Sequence typeRepetition time TR (ms)Echo time TE (MS) 1.5 TFlip angle (^0^)Matrix sizeNumber of slicesField of view (FOV) (MM)Pixel size (mm x mm)Number of averagesAcquisition time (min:s)**Precontrast, high-resolution 3D T~1~-weighted8.94.235512 × 384603400.66 × 0.8912Dynamic contrast enhanced, 3D T~1~-weighted^a^ 2 sequences before contrast injection and 6 after8.84.235256 × 256^b^4803401.33 × 1.33^b^18 × 1.10Postcontrast, high-resolution 3D T~1~-weighted with fat suppression18.94.235512 × 384603400.66 × 0.8915[^9][^10].

[^1]: *P*\<0.01, paired samples *t*-test for the difference in confidence pre- and post-2nd MRI.

[^2]: Grade Bloom & Richardson grades 1, 2 & 3 (Elston and Ellis, 1991) oestrogen receptor=ER positive (+), negative (−).

[^3]: Ductal carcinoma *in situ*=DCIS, invasive lobular carcinoma=ILC. Quadrants -- unifocal, multifocal, diffuse, subareolar position.

[^4]: cR=clinical response, mR=MRI response, pR=pathological response 1=complete response, 2=partial response, 3=static disease, 4=disease progression. Wide local excision WLE.

[^5]: Cases in which the 2nd MRI study reduced diagnostic knowledge *n*=12.

[^6]: Cases in which the MRI findings were thought to be confusing or incorrect *n*=14.

[^7]: Clinical trials (1997--2003): *Anglo-Celtic 2 Study*: doxorubicin/cyclophosphamide *vs* doxorubicin/docetaxel six cycles (Evans *et al*, 2002). \_ Docetaxel/Herceptin expanded access phase 4 assessment (Howell *et al*, 2002). Standard off study treatment: doxorubicin/cyclophosphamide six cycles.

[^8]: **Key to column headings**: Size=radiological (mammography and ultrasound) size at diagnosis, inflamm=inflammatory changes present, grade= Bloom and Richardson nuclear grade (Elston and Ellis, 1991) on core biopsy, ER=oestrogen receptor status on core biopsy, PgR=progesterone receptor status, Histology=core biopsy (CB) histology, IDC Invasive ductal carcinoma, ILC=invasive lobular carcinoma, Chemo=neoadjuvant chemotherapy regimen, cR=clinical response, mR=MRI response, pR=pathological response, CR=complete response, PR=partial response, NR=nonresponder, DP=disease progression. AC2=Anglo-Celtic 2 trial.

[^9]: Contrast injection was 0.16 mmol kg^−1^ body weight with an injection speed of 3 ml s^−1^, given after the second precontrast dynamic sequence.

[^10]: The matrix size is optimised to ensure that the acquisition time of each 3D image is 70 s.
